TLC (Nasdaq: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD®). TLC’s deep experience with liposome science allows TLC to combine onset speed and benefit duration, and improve active drug concentrations while decreasing unwanted systemic exposures. TLC’s BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX™ active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology. TLC is consistently ranked in the top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations. TLC listed on the Nasdaq Global Market (symbol: TLC) in 2018.
1997 | TLC is founded by Dr. Keelung Hong |
2002 | Lipo-Dox® is approved for treatment of ovarian cancer |
2004 | Lipo-Dox® is approved for treatment of breast cancer |
2012 | Publicly listed on Gretai Securities Market in Taiwan on 21 Dec, 2012 |
2013 | Ampholipad® is approved and launched in Taiwan |
2018 | TLC Reports Positive Top-Line Data from Phase II Clinical Trial of TLC599 in Knee Osteoarthritis Pain |
2018 | TLC is listed on the Nasdaq Global Market (symbol: TLC) in 2018 |
2020 | TLC reports positive results from Phase 2 trial of TLC590 for postsurgical pain |
2020 | TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis Pain |
2021 | InspirMed™ Inc., a newly established subsidiary that specializes in the development of inhalable liposome formulation programs, such as TLC19, for severe acute and chronic pulmonary diseases. |
2021 | TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India. |